Gardasil to be a $10 billion earner if approved for male patients: analyst

Share this article:

Merck's human papillomavirus vaccine Gardasil could become a blockbuster 10 times over if the drugmaker can win approval for use of the treatment in men.

With Gardasil use rising faster than that of any new vaccine, administering it to boys and young men as well as girls could push annual sales potential above $10 billion, according to Lisa Kelly, an analyst at Wood Mackenzie Consultants Ltd. in Edinburgh, Scotland.

If Kelly's estimates are correct, it would make Gardasil Merck's best-selling product, far bypassing Singulair which had sales of $3 billion in 2006.

Merck is currently conducting studies to prove that Gardasil can prevent the spread of HPV infections in men. 

Meanwhile analysts estimate that Gardasil may generate as much as $1.4 billion in its first full year on the market as regulators across the globe endorse the vaccine as a means to prevent cervical cancer caused by the sexually transmitted human papillomavirus.

Share this article:
close

Next Article in News

Email Newsletters

More in News

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.

Amgen Q2 sales rise, company to lay off up to 2,900

Amgen Q2 sales rise, company to lay off ...

The majority of the layoffs will be in the US.

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...